Anti-Helminthic Medication Safety in G6PD Deficiency
Drug-induced hemolysis in G6PD deficiency is triggered by a small group of oxidant medications. Solid evidence supports avoiding specific agents that have been linked to hemolysis in G6PD deficiency. [1]
Medications With Solid Evidence of Hemolysis Risk (Avoidance)
- Dapsone: Avoidance is recommended because it has solid evidence of causing hemolysis in G6PD deficiency. [1]
Common Anti-Helminthic Agents Considered Probably Safe at Therapeutic Doses
A 3-category evidence-based review concluded that medications outside the small “solid evidence” unsafe group can generally be given safely at usual therapeutic doses when no other contraindications exist. [1]
Common anti-helminthic agents that are not among the 7 medications with solid evidence of prohibition in that review include the following. [1]
- Albendazole. [1]
- Mebendazole. [1]
- Pyrantel (pamoate). [1]
- Praziquantel. [1]
- Ivermectin. [1]
Practical Prescription Rule for Selection
Anti-helminthic selection in G6PD deficiency should exclude agents with solid evidence of hemolysis risk. [1]
Key Evidence Supporting Avoidance
The evidence-based review identified only seven currently used medications with solid evidence requiring prohibition in G6PD deficiency. [1]
The excluded list of seven solid-evidence “avoid” drugs includes dapsone. [1]
Monitoring Considerations
Hemolysis risk should be considered when any potentially oxidant drug is used in G6PD deficiency. [1]
Hemolysis is typically clinically assessed by new anemia and hemolysis markers during the course of treatment. [1]
Common Pitfalls to Avoid
-
Using dapsone for helminth-related indications in patients with G6PD deficiency. [1]
-
Assuming “anti-parasitic” automatically implies safety because not all antiparasitic drugs have the same hemolysis risk. [1]
Targets for Safe Therapy
Safe anti-helminthic therapy in G6PD deficiency is achieved by selecting agents not in the solid-evidence hemolysis “avoid” group and using standard therapeutic dosing. [1]